Q-omics provides the consensus-scored C2orf80 profile across patient tissues and cancer cell-line models. C2orf80 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C2orf80 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, C2orf80 RNA expression shows 7,940 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where C2orf80 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2orf80 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2orf80 survival associations across molecular data types. C2orf80 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2orf80 RNA expression–survival associations across cancer types. High C2orf80 expression shows unfavorable associations in ACC, UCEC, BRCA and KIRP, but favorable associations in LUAD and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C2orf80 RNA expression.
This table summarizes C2orf80 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C2orf80. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2orf80 shows lower tumor expression in COAD, KICH, PRAD and KIRC and higher tumor expression in HNSC and THCA. The COAD box plot shows higher C2orf80 RNA expression in normal versus tumor tissue (log2 FC = −0.109, t-test p < 0.001).
This table shows molecular features associated with C2orf80 in patient tissues and cancer cell lines. In patient samples, C2orf80 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, C2orf80 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
